摘要
达比加群酯是新型的口服直接凝血酶抑制剂,具有强效抗凝、出血风险低、无需特殊监测、药物相互作用少等优点,目前已成为临床研究的热点。该文综述了近年来相关的作用机制、药代动力学、临床应用等方面的研究,为达比加群酯的后续研究提供参考。
Dabigatran etexilate is a novel direct oral thrombin inhibitor. The drug has a strong anticoagulant feature, low risk of bleeding, no need for special monitoring, few drug interactions and other advantages and become a hot spot in clinical research. In this paper, the mechanism of action, pharmacokinetics, clinical application and other aspects are reviewed to provide reference for the further research of dabigatran etexilate.
出处
《中国药业》
CAS
2017年第2期4-7,共4页
China Pharmaceuticals
基金
佳木斯大学研究生科技创新项目[LZR2015_023]
关键词
达比加群酯
抗凝
临床研究
进展
dabigatran etexilate
anticoagulation
clinical research
progress
